Document is current
Any future updates will be listed below
-
Authors
Tang, Hongwei
Yan, Huihuang https://orcid.org/0000-0003-0756-2922
Shivaram, Suganti
Lehman, Stacey
Sharma, Neeraj https://orcid.org/0000-0002-8229-3083
Smadbeck, James
Zepeda-Mendoza, Cinthya
Tian, Shulan
Asmann, Yan
Vachon, Celine https://orcid.org/0000-0002-1962-9322
Gaspar Maia, Alexandre https://orcid.org/0000-0001-8528-5575
Keats, Jonathan https://orcid.org/0000-0003-4375-7399
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Stewart, A. Keith
Hsu, Joel-Sean
Kandasamy, Richard K. https://orcid.org/0000-0002-0894-1222
Pandey, Akhilesh https://orcid.org/0000-0001-9943-6127
Kaddoura, Marcella A.
Maura, Francesco https://orcid.org/0000-0002-5017-1620
Mitra, Amit https://orcid.org/0000-0003-4046-7070
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
Elhaik, Eran
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Baughn, Linda B. https://orcid.org/0000-0001-5229-4897
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R37CA272883)
- License Information
-
More Information
Article History
Received: 8 May 2024
Revised: 18 July 2024
Accepted: 23 July 2024
First Online: 14 October 2024
Competing interests
: SKK served as a consultant for Celgene, Takeda, Amgen, Janssen, and Bristol-Myers Squibb, and received research funding from Celgene, Takeda, Novartis, Amgen, AbbVie, Janssen, and Bristol-Myers Squibb. LBB served as a consultant for Genentech. Eran Elhaik is a consultant at the DNA Diagnostics Centre. AKS Amgen, Glaxo Smith Klein, Genentech, Janssen, Ono, Skyline Diagnostics, Tempus Labs Inc. RF Consulting: AbbVie, Adaptive Biotechnologies, AMGEN, AZeneca, Bayer, Binding Site, BMS (Celgene), Millenium Takeda, Jansen, Juno, Kite, Merck, Pfizer, Pharmacyclics, RA Capital, Regeneron, Sanofi. Scientific Advisory Boards: Adaptive Biotechnologies, Caris Life Sciences, Oncotracker. Board of Directors: Antegene (for profit), AZBio (not for Profit), patent for FISH in MM. The remaining authors declare no competing financial interests relevant to the project.
